Acute canine model for drug-induced torsades de pointes in drug safety evaluation - Influences of anesthesia and validation with quinidine and astemizole

Toxicological Sciences

Volumn 60, Issue 1, 2001, Pages 165-176

  Yamamoto, K ^a   Tamura, T ^a   Imai, R ^a   Yamamoto, M ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Anesthesia; Astemizole; Dog model; Drug safety; Quinidine; Torsades de pointes

Indexed keywords

ALMOKALANT; AMIODARONE; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; DISOPYRAMIDE; ERYTHROMYCIN; HALOTHANE; ISOFLURANE; ISOPRENALINE; NITROUS OXIDE; OXYGEN; PENTOBARBITAL; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; QUINIDINE; SOTALOL; TERFENADINE; THIOPENTAL;

ANESTHESIA; ANIMAL MODEL; ARTICLE; COMPLETE HEART BLOCK; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SCREENING; ELECTROSTIMULATION; EXTRASYSTOLE; FEMALE; HEART ARRHYTHMIA; IN VIVO STUDY; INCIDENCE; MALE; NONHUMAN; QT INTERVAL; RISK ASSESSMENT; TORSADE DES POINTES; VALIDATION PROCESS;

ACUTE DISEASE; ANESTHESIA; ANESTHETICS, INHALATION; ANIMALS; ASTEMIZOLE; ATRIOVENTRICULAR NODE; CATHETER ABLATION; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTRIC STIMULATION; ELECTROCARDIOGRAPHY; FEMALE; HALOTHANE; HEART BLOCK; ISOFLURANE; LONG QT SYNDROME; MALE; PENTOBARBITAL; QUINIDINE; SENSITIVITY AND SPECIFICITY; TORSADES DE POINTES;

ANIMALIA; CANIS FAMILIARIS;

EID: 0035097707     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/60.1.165     Document Type: Article

References (60)

1. MiRP forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
2. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart
3. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes
4. K(V)LQT1 and 1sK (minK) proteins associate to form the I(Ks) cardiac potassium current
5. Torsade de pointes due to quinidine: Observations in 31 patients
6. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): Case report and review
7. Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide
8. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes
9. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine
10. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
11. Quinidine-induced action potential prolongation, early afterdepolarizations and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium
12. Effect of pentobarbital anesthesia on vulnerability to ventricular fibrillation
13. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval
14. + channels
15. Experimental models of torsade de pointes
16. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns
17. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: Detailed analysis of ventricular tridimensional activation patterns
18. The long QT syndrome and torsade de pointes
19. Die systolendauer in elektrokardiogramm bei nomalen menschen und bei herzkranken
20. Effects of halothane and quinidine on intracardiac conduction and QTc interval in pentobarbital-anesthetized dogs
21. Electrophysiologic effects of nitrous oxide, a volatile anesthetic, in dogs following myocardial infarction in comparison with other anesthetics
22. Accidental astemizole overdose in young children
23. Comparison of effects of three anesthetic agents on induction of ventricular tachycardia in a canine model of myocardial infarction
24. Astemizole-induced torsades de pointes in a patient with vasospastic angina
25. Torsades de pointes and low-dose oral haloperidol
26. Quinidine syncope: Torsades de pointes with low quinidine plasma concentrations
27. Early afterdepolarization-like activity in patients with class IA-induced long QT syndrome and torsades de pointes
28. QT prolongation and torsades de pointes associated with clarithromycin
29. Anaesthesia and the QT interval in humans: Effects of halothane and isoflurane in premedicated children
30. QT interval prolongation and torsades de pointes due to erythromycin lactobionate
31. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia
32. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres
33. Torsades de pointes ventricular tachycardia associated with overdose of astemizole
34. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length
35. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care
36. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine
37. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel
38. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel
39. Torsades de pointes associated with intravenous haloperidol in critically ill patients
40. Sodium-channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome
41. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: Effects of betaadrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes
42. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndrome
43. Astemizole-induced torsade de pointes
44. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: A double-blind, randomized parallel evaluation
45. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade
46. Torsade de pointes ventricular tachycardia associated with astemizole overdose
47. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes
48. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
49. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: A comparison between almokalant the dog as its own control
50. Role of interventricular dispersion of repolarization in acquired torsades de pointes arrhythmias: Reversal by magnesium
51. Cisapride-induced torsades de pointes
52. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes
53. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling
54. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias
55. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome
56. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol, and sotalol
57. Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome
58. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration
59. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole
60. Torsades de pointes after treatment with terfenadine and ketoconazole